MNKD

MannKind Corporation [MNKD] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

MNKD Stock Summary

Top 10 Correlated ETFs

MNKD

Top 10 Correlated Stocks

MNKD

In the News

MNKD Financial details

Company Rating
-
Market Cap
1.12B
Income
-18.16M
Revenue
198.96M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
411
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-22.42
Forward P/E
-
PEG
2.66
P/S
5.45
P/B
-3.81
P/C
-
P/FCF
-30.43
Quick Ratio
1.69
Current Ratio
2.34
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.07
EPS next Y
-
EPS next Q
-
EPS this Y
-89.84%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-32.11%
Revenue last 5Y
25.84%
Revenue Q/Q
14.09%
EPS Q/Q
-18.75%
-
-
-
-
SMA20
-14.29%
SMA50
-14.29%
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-13%
ROE
17%
ROC
-0.03%
Gross Margin
66%
Oper. Margin
-4%
Profit Margin
-24%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.17-5.75
52W High
+13%
52W Low
+88.33%
RSI
33
Rel Volume
0.03
Avg Volume
3.05M
Volume
80.21K
Perf Week
-7.53%
Perf Month
-17.52%
Perf Quarter
8.86%
Perf Half Y
8.03%
-
-
-
-
Beta
1.323
-
-
Volatility
0.2%, 0.37%
Prev Close
1.07%
Price
5.65
Change
1.62%

Something similar

Top by Market Cap
TL0.DE
BRK-B
MSF.DE
GOOG
AAPL
Top Correlated ETFs
INDF
CNBS
WNDY
INDY
INDL
Top Correlated Stocks
DCBO
VRAR
ON
CTLP
GDOT
Similar Market Cap
2929.TW
PFPRX
PMZ-UN.TO
0R2C.L
DIVI

Company Profile

Healthcare Biotechnology
  • Volume Average 3.05M
  • Market Capitalization 1.12B
  • Employee 411
  • CEO Dr. Michael E. Castagna Pharm.D.
  • Headquarters Westlake Village,CA,US
  • IPO Date 2004-07-28
  • Website https://www.mannkindcorp.com

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.